

Prevalence of comedications and effect of potential drug HIV Cohort Study

Antiviral Therapy

15, 413-423

DOI: [10.3851/imp1540](https://doi.org/10.3851/imp1540)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Life expectancy of HIV-positive adults: a review. <i>Sexual Health</i> , 2011, 8, 526.	0.4	85
2	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. <i>Aids</i> , 2011, 25, 441-451.	1.0	34
3	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2107-2111.	1.3	131
4	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2011, 53, 1130-1139.	2.9	525
5	Liver disease, HIV and aging. <i>Sexual Health</i> , 2011, 8, 512.	0.4	16
6	Patients accessing HIV treatment via sexual health services: what are the risks of the dual case-note system?. <i>International Journal of STD and AIDS</i> , 2012, 23, 99-104.	0.5	6
7	HIV Coinfection With Hepatitis C Virus: Evolving Epidemiology and Treatment Paradigms. <i>Clinical Infectious Diseases</i> , 2012, 55, S33-S42.	2.9	131
8	A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. <i>International Journal of STD and AIDS</i> , 2012, 23, 546-552.	0.5	28
9	Risk Factors for Falls in HIV-Infected Persons. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 484-489.	0.9	144
10	Pill Burden in HIV Infection: 20 Years of Experience. <i>Antiviral Therapy</i> , 2012, 17, 833-840.	0.6	45
11	Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient. <i>Aids</i> , 2012, 26, 2417-2418.	1.0	20
13	Patient Perceptions of Pre-Implementation of Personal Health Records (PHRs): A Qualitative Study of People Living With HIV in New York City. <i>Journal of HIV/AIDS and Social Services</i> , 2012, 11, 406-423.	0.7	8
14	Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines. <i>Canadian Journal of Hospital Pharmacy</i> , 2012, 65, 125-45.	0.1	44
15	Prediction and In Vitro Evaluation of Selected Protease Inhibitor Antiviral Drugs as Inhibitors of Carboxylesterase 1: A Potential Source of Drug-Drug Interactions. <i>Pharmaceutical Research</i> , 2012, 29, 972-982.	1.7	27
16	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. <i>HIV Medicine</i> , 2012, 13, 1-6.	1.0	149
17	6.0€ Supporting patients on therapy. <i>HIV Medicine</i> , 2012, 13, 35-46.	1.0	1
18	Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs. <i>Current Infectious Disease Reports</i> , 2012, 14, 67-82.	1.3	46
19	Psychiatric treatment considerations with direct acting antivirals in hepatitis C. <i>BMC Gastroenterology</i> , 2013, 13, 86.	0.8	18

#	ARTICLE	IF	CITATIONS
20	Polypharmacy and Risk of Antiretroviral Drug Interactions Among the Aging HIV-Infected Population. <i>Journal of General Internal Medicine</i> , 2013, 28, 1302-1310.	1.3	105
21	The Next Therapeutic Challenge in HIV: Polypharmacy. <i>Drugs and Aging</i> , 2013, 30, 613-628.	1.3	191
22	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. <i>In Silico Pharmacology</i> , 2013, 1, 4.	1.8	26
23	Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach. <i>Clinical Pharmacokinetics</i> , 2013, 52, 583-592.	1.6	47
24	Antiretroviral pharmacology. <i>Medicine</i> , 2013, 41, 474-478.	0.2	2
25	Management of Human Immunodeficiency Virus Infection in Advanced Age. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1397.	3.8	137
26	Association of Age With Polypharmacy and Risk of Drug Interactions With Antiretroviral Medications in HIV-Positive Patients. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1429-1439.	0.9	90
27	Aging with HIV: a practical review. <i>Brazilian Journal of Infectious Diseases</i> , 2013, 17, 464-479.	0.3	72
28	Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1-3.	1.3	16
29	The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence. <i>International Journal of STD and AIDS</i> , 2013, 24, 237-241.	0.5	14
30	Safety profile of antiviral medications: A pharmacovigilance study using the Italian spontaneous-reporting database. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1039-1046.	0.5	10
31	Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1354-9.	1.3	30
32	Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. <i>Future Virology</i> , 2013, 8, 871-890.	0.9	10
33	Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy. <i>Aids</i> , 2013, 27, 1593-1602.	1.0	5
34	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian Guidelines for Management and Treatment of HIV/Hepatitis C Coinfection in Adults. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2013, 24, 217-238.	0.7	10
35	Concurrent Use of Comedications Reduces Adherence to Antiretroviral Therapy Among HIV-Infected Patients. <i>Journal of Managed Care Pharmacy</i> , 2014, 20, 844-850.	2.2	54
36	Potential drug–drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria. <i>HIV/AIDS - Research and Palliative Care</i> , 2014, 6, 49.	0.4	3
39	The relationship of physical performance with HIV disease and mortality. <i>Aids</i> , 2014, 28, 2711-2719.	1.0	72

#	ARTICLE	IF	CITATIONS
40	HIV and ageing: what the geriatrician needs to know. <i>Reviews in Clinical Gerontology</i> , 2014, 24, 10-24.	0.5	4
41	How common are drug and gene interactions? Prevalence in a sample of 1143 patients with <i>CYP2C9</i>, <i>CYP2C19</i> and <i>CYP2D6</i> genotyping. <i>Pharmacogenomics</i> , 2014, 15, 655-665.	0.6	86
42	Drug Interactions and Antiretroviral Drug Monitoring. <i>Current HIV/AIDS Reports</i> , 2014, 11, 212-222.	1.1	38
43	Polypharmacy, Drug-Drug Interactions, and Potentially Inappropriate Medications in Older Adults with Human Immunodeficiency Virus Infection. <i>Journal of the American Geriatrics Society</i> , 2014, 62, 447-453.	1.3	129
44	Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 742-748.	1.3	34
45	Drug-drug interactions in inpatient and outpatient settings in Iran: a systematic review of the literature. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2014, 22, 52.	0.9	23
47	Retention in Care Is More Strongly Associated With Viral Suppression in HIV-Infected Patients With Lower Versus Higher CD4 Counts. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 333-339.	0.9	63
48	Switch to etravirine for <sc>HIV</sc>-positive patients receiving statin treatment: a prospective study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 720-730.	1.7	5
49	Geriatric Syndromes in Older HIV-Infected Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 161-167.	0.9	192
50	Quantifying polypharmacy in a large <sc>HIV</sc>-infected cohort. <i>HIV Medicine</i> , 2015, 16, 583-584.	1.0	9
51	HIV Infection and AIDS: Antiretroviral Therapy. , 2015, , 397-410.		0
52	Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv259.	1.3	18
53	Prevalence of concomitant medications in older HIV+ patients and comparison with general population. <i>HIV Clinical Trials</i> , 2015, 16, 117-124.	2.0	30
54	The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60-years of age. <i>HIV Clinical Trials</i> , 2015, 16, 39-42.	2.0	10
55	Identification of potential clinically significant drug interactions in <sc>HIV</sc>-infected patients: a comprehensive therapeutic approach. <i>HIV Medicine</i> , 2015, 16, 273-279.	1.0	21
56	The financial and service implications of splitting fixed-dose antiretroviral drugs - a case study. <i>International Journal of STD and AIDS</i> , 2015, 26, 75-80.	0.5	0
57	Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 471-479.	1.5	10
58	Heart failure in patients with human immunodeficiency virus. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 383-389.	0.6	14

#	ARTICLE	IF	CITATIONS
60	CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-34.	0.7	21
61	Polypharmacy in older adults with human immunodeficiency virus infection compared with the general population. Clinical Interventions in Aging, 2016, Volume 11, 1149-1157.	1.3	46
62	HIV Infection in the Elderly: Arising Challenges. Journal of Aging Research, 2016, 2016, 1-10.	0.4	27
63	More than osteoporosis. Current Opinion in HIV and AIDS, 2016, 11, 343-350.	1.5	15
64	Design and validation of a predictive model for 1-year hospital admission in HIV patients on antiretroviral treatment. European Journal of Hospital Pharmacy, 2016, 23, 224-227.	0.5	3
65	The clinical implications of <scp>HIV</scp> infection and aging. Oral Diseases, 2016, 22, 79-86.	1.5	6
66	British HIV Association guidelines for the treatment of <scp>HIV</scp>â€”positive adults with antiretroviral therapy 2015. HIV Medicine, 2016, 17, s2-s104.	1.0	78
67	Understanding HIV-positive patients' preferences for healthcare services: a protocol for a discrete choice experiment. BMJ Open, 2016, 6, e008549.	0.8	4
68	Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty. Journal of Visualized Experiments, 2016, , .	0.2	14
69	Aging and influence of inversion of the CD4:CD8 ratio in the incidence of co-morbidities and mortality in a cohort of patients infected with human immunodeficiency virus. Medicina ClÃnica (English) Tj ETQq1 1 0.784304rgBT /Overlock 10		
70	The Impact of Non-Antiretroviral Polypharmacy on the Continuity of Antiretroviral Therapy (ART) Among HIV Patients. AIDS Patient Care and STDs, 2016, 30, 11-17.	1.1	43
72	Identifying high risk medications causing potential drugâ€”drug interactions in outpatients: A prescription database study based on an online surveillance system. Research in Social and Administrative Pharmacy, 2016, 12, 559-568.	1.5	23
73	Effect of drug interactions involving antiretroviral drugs on viral load in HIV population. European Journal of Hospital Pharmacy, 2016, 23, 241-243.	0.5	1
74	An observational study of comorbidity and healthcare utilisation among HIV-positive patients aged 50 years and over. International Journal of STD and AIDS, 2016, 27, 628-637.	0.5	18
75	Managing potential drug-drug interactions between gastric acid-reducing agents and antiretroviral therapy: experience from a large HIV-positive cohort. International Journal of STD and AIDS, 2016, 27, 105-109.	0.5	14
76	Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients. Annals of Pharmacotherapy, 2017, 51, 365-372.	0.9	21
77	The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. Aids, 2017, 31, S173-S184.	1.0	26
78	The changing face of an epidemic: healthy old age with HIV. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 516-522.	0.2	3

#	ARTICLE	IF	CITATIONS
79	Ageing with <scp>HIV</scp>: do comorbidities and polymedication drive treatment optimization?. HIV Medicine, 2017, 18, 395-401.	1.0	22
80	Use of non-antiretroviral drugs among individuals with and without HIV-infection: a Danish nationwide study. Infectious Diseases, 2017, 49, 42-54.	1.4	7
81	Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. Clinical Pharmacokinetics, 2017, 56, 409-420.	1.6	18
82	Incidence, clinical presentation, and outcome of HIV-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: a nationwide cohort study. Clinical Epidemiology, 2017, Volume 9, 385-392.	1.5	7
83	Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection. PLoS ONE, 2017, 12, e0173509.	1.1	29
84	Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	17
85	Antiretroviral pharmacology. Medicine, 2018, 46, 287-292.	0.2	2
86	Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy. Open Forum Infectious Diseases, 2018, 5, ofy032.	0.4	12
87	Analysis of self-reported adverse reactions to efavirenz and drug interactions in a population with HIV in Mexico. European Journal of Hospital Pharmacy, 2018, 25, 322-326.	0.5	4
88	Patients's perspectives on the development of HIV services to accommodate ageing with HIV: a qualitative study. International Journal of STD and AIDS, 2018, 29, 483-490.	0.5	10
89	Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team. HIV Clinical Trials, 2018, 19, 1-7.	2.0	21
90	Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. Aids, 2018, 32, 35-48.	1.0	60
91	Burden of Exposure to Potential Interactions Between Antiretroviral and Non-Antiretroviral Medications in a Population of HIV-Positive Patients Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 193-201.	0.9	24
92	Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda. BMC Geriatrics, 2018, 18, 125.	1.1	24
93	Drug-drug interactions when treating HIV-related metabolic disorders. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 787-802.	1.5	6
94	Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Côte d'Ivoire, West Africa: A cross-sectional study. PLoS ONE, 2019, 14, e0221335.	1.1	0
95	Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	21
96	Polypharmacy and Drug-Drug Interactions in Older and Younger People Living with HIV: The POPPY Study. Antiviral Therapy, 2019, 24, 193-201.	0.6	44

#	ARTICLE	IF	CITATIONS
97	Choosing appropriate pharmacotherapy for drug-resistant HIV. Expert Opinion on Pharmacotherapy, 2019, 20, 667-678.	0.9	10
98	Disparities in Viral Suppression and Medication Adherence among Women in the USA, 2011–2016. AIDS and Behavior, 2019, 23, 3015-3023.	1.4	26
99	Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study. Frontiers in Pharmacology, 2019, 10, 265.	1.6	31
100	Contemporary Drug–Drug Interactions in HIV Treatment. Clinical Pharmacology and Therapeutics, 2019, 105, 1362-1377.	2.3	16
101	The influence of age-associated comorbidities on responses to combination antiretroviral therapy in older people living with HIV. Journal of the International AIDS Society, 2019, 22, e25228.	1.2	13
102	Comorbidity and polypharmacy among women living with HIV in British Columbia. Aids, 2019, 33, 2317-2326.	1.0	10
103	Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. Open Forum Infectious Diseases, 2019, 6, ofz531.	0.4	38
104	Polypharmacy among HIV infected people aged 50 years or older. Colombia Medica, 2019, 50, 142-152.	0.7	7
105	Greater burden of chronic comorbidities and co-medications among people living with HIV versus people without HIV in Japan: A hospital claims database study. Journal of Infection and Chemotherapy, 2019, 25, 89-95.	0.8	28
106	HIV-infected patients aged above 75 years. Médecine Et Maladies Infectieuses, 2020, 50, 43-48.	5.1	8
107	Polypharmacy and Drug–Drug Interactions in People Living With Human Immunodeficiency Virus in the Region of Madrid, Spain: A Population-Based Study. Clinical Infectious Diseases, 2020, 71, 353-362.	2.9	52
108	Prevalence and management of drug–drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study. HIV Medicine, 2020, 21, 53-63.	1.0	15
109	Deprescribing of non-antiretroviral therapy in HIV-infected patients. European Journal of Clinical Pharmacology, 2020, 76, 305-318.	0.8	19
110	Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions. Irish Journal of Medical Science, 2020, 189, 693-699.	0.8	4
111	Potential drug–drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir. Medicina Clínica (English Edition), 2020, 155, 281-287.	0.1	8
112	Interacciones medicamentosas potenciales en pacientes COVID 19 en tratamiento con lopinavir/ritonavir. Medicina Clínica, 2020, 155, 281-287.	0.3	7
113	Evolution of Drug Interactions With Antiretroviral Medication in People With HIV. Open Forum Infectious Diseases, 2020, 7, ofaa416.	0.4	15
114	Pharmacists' role in HIV care in France. Implication for clinical improvement of people living with HIV worldwide. Pharmacology Research and Perspectives, 2020, 8, e00629.	1.1	5

#	ARTICLE	IF	CITATIONS
115	Use of comedICATIONS and potential drug-drug interactions in people living with HIV in China. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 722-728.	0.8	6
116	The Challenge of Potential Drug-Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China. <i>Frontiers in Pharmacology</i> , 2020, 11, 800.	1.6	2
117	Monitoring of older HIV-positive adults by HIV clinics in the United Kingdom: a national quality improvement initiative. <i>HIV Medicine</i> , 2020, 21, 409-417.	1.0	4
118	Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. <i>Clinical Infectious Diseases</i> , 2021, 73, e2145-e2152.	2.9	9
119	Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 270-278.	0.9	8
120	Potential drug-drug interactions in patients with indication for prophylactic implantation of a cardioverter defibrillator: a cross-sectional analysis. <i>BMC Health Services Research</i> , 2020, 20, 271.	0.9	2
121	Fighting on two fronts: drug-drug interactions in people living with HIV infected with SARS-CoV-2. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, e3-e3.	0.5	3
122	Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 471-484.	2.3	10
123	High level of medication regimen complexity index correlate with worse quality of life in people living with HIV. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 93-99.	0.5	11
124	Higher plasma drug levels in elderly people living with HIV treated with darunavir. <i>PLoS ONE</i> , 2021, 16, e0246171.	1.1	5
125	Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. <i>Scientific Reports</i> , 2021, 11, 12414.	1.6	14
126	Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2681-2689.	1.3	2
127	Structured medicines reviews in HIV outpatients: a feasibility study (The MOR Study). <i>HIV Medicine</i> , 2021, , .	1.0	2
128	Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort. <i>PLoS ONE</i> , 2011, 6, e16800.	1.1	39
129	Characteristics and outcomes of older HIV-infected patients receiving antiretroviral therapy in Malawi: A retrospective observation cohort study. <i>PLoS ONE</i> , 2017, 12, e0180232.	1.1	12
130	Analysis of Potential Interaction between Antiretrovirals and Comorbid Medications of HIV Patients at a Top Referral Hospital in Indonesia. <i>Open AIDS Journal</i> , 2020, 14, 68-74.	0.1	1
131	CLINICALLY SIGNIFICANT DRUG-DRUG INTERACTION IN A LARGE ANTIRETROVIRAL TREATMENT CENTRE IN LAGOS, NIGERIA. <i>Canadian Journal of Clinical Pharmacology</i> , 2019, 26, e1-e19.	1.1	13
133	Facilitating primary care non-antiretroviral drug prescribing in people living with HIV: The THINK ARV™ initiative. <i>International Journal of STD and AIDS</i> , 2021, , 095646242110473.	0.5	0

#	ARTICLE	IF	CITATIONS
135	Non-ARV Prescriptions and Medication Burden among Commercially Insured U.S. HIV Patients. Journal of Pharmaceutics and Drug Development, 2014, 1, .	0.1	0
136	HIV-Associated Comorbidities. , 2016, , 9-13.		0
137	Prevalence of prescription of the Top-10 drug classes to avoid in elderly people living with HIV in a real practice cohort. Revista Espanola De Quimioterapia, 2021, 34, 28-32.	0.5	3
138	Prevalence, predictors and outcomes of potential drug-drug interactions in left ventricular failure: considerable factors for quality use of medicines. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	0
139	Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors. Current HIV Research, 2020, 18, 415-425.	0.2	2
140	Influence of pharmacist intervention, based on CMO model, to improve activation in HIV patients. Revista Espanola De Quimioterapia, 2019, 32, 40-49.	0.5	5
141	Determination of a cutoff value for medication regimen complexity index to predict polypharmacy in HIV+ older patient. Revista Espanola De Quimioterapia, 2019, 32, 458-464.	0.5	13
142	Potential drug-drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 43.	0.4	2
143	Prevalence of comorbidities and concomitant medication use in acromegaly: analysis of real-world data from the United States. Pituitary, 2022, 25, 296-307.	1.6	17
144	Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naïve adults with HIV-1 infection. BMC Infectious Diseases, 2022, 22, 17.	1.3	5
145	Novel bivalent ligands carrying potential antinociceptive effects by targeting putative mu opioid receptor and chemokine receptor CXCR4 heterodimers. Bioorganic Chemistry, 2022, 120, 105641.	2.0	5
146	Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices. Pharmaceuticals, 2022, 15, 242.	1.7	3
148	Evolving patterns of antiretroviral drug interactions in people living with HIV in British Columbia, Canada. Aids, 2022, Publish Ahead of Print, .	1.0	1
149	Potential or contraindicated drug-drug interactions with antiretroviral therapy in real-world settings in Taiwan. Journal of the Formosan Medical Association, 2022, 121, 1714-1720.	0.8	2
151	Drug-drug interactions with antiretroviral therapy among people living with HIV in Asia and other regions: risk factors and impact on indicators of health-related quality of life. Population Medicine, 2022, 4, .	0.3	0
152	Quality of life and associated factors among people receiving second-line anti-retroviral therapy in Johannesburg, South Africa. BMC Infectious Diseases, 2022, 22, 456.	1.3	3
153	Potential drug-drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey. HIV Medicine, 2023, 24, 46-54.	1.0	4
154	Interazioni farmacologiche degli inibitori delle integrasi tra le persone anziane che vivono con HIV.. JHA - Journal of HIV and Ageing, 2022, , .	0.0	0

#	ARTICLE	IF	CITATIONS
155	Clinically significant drug interactions between antiretroviral and co-prescribed drugs in HIV infected patients: retrospective cohort study. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.2	1
156	Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment. <i>AIDS and Behavior</i> , 2023, 27, 119-133.	1.4	5
157	Do ART and Chemsex Drugs Get Along? Potential Drug-Drug Interactions in a Cohort of People Living with HIV Who Engaged in Chemsex: A Retrospective Observational Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 2111-2124.	1.8	8
158	Influence of polypharmacy in the simultaneous presence of high pharmacotherapeutic complexity, drug interactions and non-adherence to medication in patients with HIV infection. <i>Project 3-HIT. Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2022, , .	0.2	0
159	Drug-Drug-Gene Interactions in Cardiovascular Medicine. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 15, 879-911.	0.4	3
160	Antiretroviral therapy. , 2023, , 263-283.		0
161	Potential drug-drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 1541-1553.	1.1	2
162	Pharmacist-Involved Antiretroviral Stewardship Programs in People Living with HIV/AIDS: A Systematic Review. <i>AIDS Patient Care and STDs</i> , 2023, 37, 31-52.	1.1	5
163	Evaluation of health literacy and medication regimen complexity index among patients with human immunodeficiency virus infection: A single-Centre, prospective, cross-sectional study. <i>Clinical Epidemiology and Global Health</i> , 2023, 19, 101206.	0.9	0
164	Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2023, 92, 97-105.	0.9	3
165	Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 2236-2245.	1.1	2
166	Polypharmacy and health related quality of life among older adults on antiretroviral therapy in a tertiary hospital in Tanzania: a hospital-based cross-sectional study. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	1
167	Drug-Drug Interactions and the Risk of Emergency Hospitalizations: A Nationwide Population-Based Study. <i>Drug Safety</i> , 0, , .	1.4	2
170	HIV Infection and AIDS: The Present Status of Antiretroviral Therapy. , 2023, , 429-442.		0